We are committed to extending and enhancing the lives of people living with blood cancers.
Our science, expertise, and commitment to transforming the treatment landscape of blood cancers drives our single-minded urgency to deliver innovative therapies to patients.
Clinical trials
To learn about our clinical trials, click here.
To see clinical trials that are currently underway and to find out if a study is enrolling patients with your condition and in your area, please visit www.clinicaltrials.gov.
To learn more about cancer clinical trials, please visit Cancer.gov.
Expanded Access Policy
Geron is committed to advancing innovative therapies for people living with serious blood cancers. For approved medicines in their indicated uses, patients access treatment through established healthcare and reimbursement pathways.
It is our duty to carefully evaluate the safety and efficacy of any potential new medicines for a particular disease area. We believe clinical trials are the best and most appropriate way to do that. When successful, data from these studies form the basis of regulatory (i.e. FDA, EMA, or similar regulatory agencies) approvals, which ensure sustained access to the medications patients need.
We also recognize that patients and physicians may seek access to investigational medicines outside of clinical trials. While participating in clinical studies remains the primary and most appropriate pathway for accessing investigational therapies, Geron may consider requests for expanded access (also known as early access, compassionate use, or named patient program) in certain circumstances, guided by patient availability for that medicine in their country, patient need, scientific evidence, available drug supply, and applicable regulations.
Geron continues to assess the eligibility requirements and criteria for Expanded Access to imetelstat. At this time, a United States Expanded Access Program (EAP) or Compassionate Use Program is not available for any disease area. To inquire about programs outside of the United States, please email [email protected] and we will acknowledge receipt of your request within 3 business days. We will re-evaluate this policy from time to time.
About Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes (MDS) are a group of blood cancers caused by disruption of normal hematopoiesis in the bone marrow, where not enough healthy blood cells are made, and are characterized by cytopenias (such as anemia), risk of progression to acute myeloid leukemia (AML), and mortality.
Lower-risk myelodysplastic syndromes (LR-MDS) is a blood cancer that often progresses to require increasingly intensified management of key symptoms such as anemia and resulting fatigue. These symptomatic LR-MDS patients frequently become red blood cell transfusion dependent, which has been shown to be associated with short- and long-term clinical consequences that reduce quality of life and shorten survival. There is a high unmet need for many LR-MDS patients, particularly those with characteristics having poorer prognosis.
About Myelofibrosis (MF)
Patients with MF are typically treated with Janus-associated kinase inhibitors (JAKis). Unfortunately, the majority of patients become unresponsive to JAKis within five years, resulting in very poor overall survival prognosis. These patients have high unmet need for treatments that can extend survival.
About Acute Myeloid Leukemia (AML)
The current treatment approach for AML consists of chemotherapy (anthracycline plus cytarabine), an approach that has been largely unchanged for more than 40 years, or chemotherapy plus a targeted therapy against specific mutations. Despite initial response to these treatments, the majority of AML patients will suffer a relapse, at which point the condition is incurable with standard therapy. New treatments that can improve outcomes after chemotherapy are critical to extending and enhancing the lives of patients with AML.
Exploring the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies
Learn how we’re building on Nobel Prize-winning science